348 related articles for article (PubMed ID: 28591206)
21. Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease.
Phalen DN; Frimberger AE; Peck S; Pyecroft S; Harmsen C; Lola S; Moore AS
Vet J; 2015 Dec; 206(3):312-6. PubMed ID: 26538144
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Biomarkers for Tasmanian Devil Cancer (DFTD) by Metabolic Profiling of Serum.
Karu N; Wilson R; Hamede R; Jones M; Woods GM; Hilder EF; Shellie RA
J Proteome Res; 2016 Oct; 15(10):3827-3840. PubMed ID: 27599268
[TBL] [Abstract][Full Text] [Related]
23. Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population.
Pearse AM; Swift K; Hodson P; Hua B; McCallum H; Pyecroft S; Taylor R; Eldridge MD; Belov K
Cancer Genet; 2012 Mar; 205(3):101-12. PubMed ID: 22469509
[TBL] [Abstract][Full Text] [Related]
24. No evidence that a transmissible cancer has shifted from emergence to endemism in Tasmanian devils.
Stammnitz MR; Gori K; Murchison EP
R Soc Open Sci; 2024 Apr; 11(4):231875. PubMed ID: 38633353
[TBL] [Abstract][Full Text] [Related]
25. The role of MHC genes in contagious cancer: the story of Tasmanian devils.
Caldwell A; Siddle HV
Immunogenetics; 2017 Aug; 69(8-9):537-545. PubMed ID: 28695294
[TBL] [Abstract][Full Text] [Related]
26. Devil Facial Tumor Disease.
Pye RJ; Woods GM; Kreiss A
Vet Pathol; 2016 Jul; 53(4):726-36. PubMed ID: 26657222
[TBL] [Abstract][Full Text] [Related]
27. High blood lead concentrations in captive Tasmanian devils (Sarcophilus harrisii): a threat to the conservation of the species?
Hivert LG; Clarke JR; Peck SJ; Lawrence C; Brown WE; Huxtable SJ; Schaap D; Pemberton D; Grueber CE
Aust Vet J; 2018 Nov; 96(11):442-449. PubMed ID: 30370598
[TBL] [Abstract][Full Text] [Related]
28. Transmissible cancer and longitudinal telomere dynamics in Tasmanian devils (Sarcophilus harrisii).
Madsen T; Klaassen M; Raven N; Dujon AM; Jennings G; Thomas F; Hamede R; Ujvari B
Mol Ecol; 2022 Dec; 31(24):6531-6540. PubMed ID: 36205590
[TBL] [Abstract][Full Text] [Related]
29. Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours.
Ong CEB; Cheng Y; Siddle HV; Lyons AB; Woods GM; Flies AS
Open Biol; 2022 Oct; 12(10):220208. PubMed ID: 36259237
[TBL] [Abstract][Full Text] [Related]
30. The effects of season and devil facial tumour disease on the reproductive physiology of the male Tasmanian devil (Sarcophilus harrisii).
Keeley T; McGreevy PD; O'Brien JK
Reprod Fertil Dev; 2012; 24(7):999-1007. PubMed ID: 22935161
[TBL] [Abstract][Full Text] [Related]
31. Pasteurellaceae bacteria from the oral cavity of Tasmanian devils (Sarcophilus Harrisii) show high minimum inhibitory concentration values towards aminoglycosides and clindamycin.
Gutman N; Hansen MJ; Bertelsen MF; Bojesen AM
Lett Appl Microbiol; 2016 Mar; 62(3):237-42. PubMed ID: 26744057
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.
Flies AS; Lyons AB; Corcoran LM; Papenfuss AT; Murphy JM; Knowles GW; Woods GM; Hayball JD
Front Immunol; 2016; 7():581. PubMed ID: 28018348
[TBL] [Abstract][Full Text] [Related]
33. Immunoglubolin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii).
Ujvari B; Hamede R; Peck S; Pemberton D; Jones M; Belov K; Madsen T
Sci Rep; 2016 Apr; 6():25093. PubMed ID: 27126067
[TBL] [Abstract][Full Text] [Related]
34. HEMATOLOGICAL AND SERUM BIOCHEMICAL VALUES IN ANESTHETIZED CAPTIVE TASMANIAN DEVILS (SARCOPHILUS HARRISII).
Hope KL; Peck S
J Zoo Wildl Med; 2016 Jun; 47(2):564-72. PubMed ID: 27468030
[TBL] [Abstract][Full Text] [Related]
35. Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.
Woods GM; Howson LJ; Brown GK; Tovar C; Kreiss A; Corcoran LM; Lyons AB
J Immunol; 2015 Jul; 195(1):23-9. PubMed ID: 26092814
[TBL] [Abstract][Full Text] [Related]
36. Comparative Cytogenetic Mapping and Telomere Analysis Provide Evolutionary Predictions for Devil Facial Tumour 2.
Ingles ED; Deakin JE
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32354058
[TBL] [Abstract][Full Text] [Related]
37. Salmonella in captive and wild Tasmanian devils (Sarcophilus harrisii) in Tasmania.
Michael SA; Harlock M; Peck SJ; Lazenby B; Pemberton D
Aust Vet J; 2020 Jun; 98(6):239-242. PubMed ID: 32090318
[TBL] [Abstract][Full Text] [Related]
38. Isotopic niche variation in Tasmanian devils
Bell O; Jones ME; Cunningham CX; Ruiz-Aravena M; Hamilton DG; Comte S; Hamede RK; Bearhop S; McDonald RA
Ecol Evol; 2021 Jun; 11(12):8038-8053. PubMed ID: 34188870
[TBL] [Abstract][Full Text] [Related]
39. Season, weight, and age, but not transmissible cancer, affect tick loads in the endangered Tasmanian devil.
Belkhir S; Hamede R; Thomas F; Ujvari B; Dujon AM
Infect Genet Evol; 2022 Mar; 98():105221. PubMed ID: 35065301
[TBL] [Abstract][Full Text] [Related]
40. Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies.
Tovar C; Obendorf D; Murchison EP; Papenfuss AT; Kreiss A; Woods GM
Vet Pathol; 2011 Nov; 48(6):1195-203. PubMed ID: 21383118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
